Search

Your search keyword '"Santos-Gomez M"' showing total 9 results
Start Over Author "Santos-Gomez M"
9 results on '"Santos-Gomez M"'

2. Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia

Author

Sorigue M, Magnano L, Miljkovic MD, Nieto-Moragas J, Santos-Gomez M, Villamor N, Junca J, and Morales-Indiano C

Subjects
immune system diseases, hemic and lymphatic diseases, CD200, flow cytometry, lymphoproliferative, predictive value, systematic review, neoplasms
Abstract

The role of CD200 in the differential diagnosis of chronic lymphocytic leukemia (CLL) and classical mantle cell lymphoma (MCL) is well established. Its role in the differential diagnosis of CLL and other lymphoproliferative disorders (LPD) is less clear, in particular its positive predictive value (PPV).

Published
2020

3. Flow Cytometry in the Differential Diagnosis of CD10-Positive Nodal Lymphomas

Author

Sorigue M, Santos-Gomez M, Comes M, Raya M, Vergara S, Tapia G, Navarro JT, Morales-Indiano C, and Junca J

Subjects
CD10, diffuse large B-cell lymphoma, flow cytometry, follicular lymphoma, high-grade B-cell lymphoma, light scatter, immune system diseases, hemic and lymphatic diseases
Abstract

Differences between follicular lymphoma (FL) and diffuse large B-cell lymphoma/high-grade B-cell lymphoma (DLBCL/HGBL) by flow cytometry are underexplored.

Published
2020

4. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy A Multicenter Study of Twenty-Five Patients

Author

Calvo-Rio, V, Santos-Gomez, M, Calvo, I, Gonzalez-Fernandez, MI, Lopez-Montesinos, B, Mesquida, M, Adan, A, Hernandez, MV, Maiz, O, Atanes, A, Bravo, B, Modesto, C, Diaz-Cordoves, G, Palmou-Fontana, N, Loricera, J, Gonzalez-Vela, MC, Demetrio-Pablo, R, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R

Subjects
genetic structures, eye diseases
Abstract

Objective. To assess the efficacy of tocilizumab (TCZ) for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis. Methods. We conducted a multicenter study of patients with JIA-associated uveitis that was refractory to conventional immunosuppressive drugs and anti-tumor necrosis factor (anti-TNF) agents. Results. We assessed 25 patients (21 female; 47 affected eyes) with a meanSD age of 18.5 +/- 8.3 years. Uveitis was bilateral in 22 patients. Cystoid macular edema was present in 9 patients. Ocular sequelae found at initiation of TCZ included cataracts (n=13), glaucoma (n=7), synechiae (n=10), band keratopathy (n=12), maculopathy (n=9), and amblyopia (n=5). Before TCZ, patients had received corticosteroids, conventional immunosuppressive drugs, and biologic agents (median 2 [range 1-5]), including adalimumab (n=24), etanercept (n=8), infliximab (n=7), abatacept (n=6), rituximab (n=2), anakinra (n=1), and golimumab (n=1). Patients received 8 mg/kg TCZ intravenously every 4 weeks in most cases. TCZ yielded rapid and maintained improvement in all ocular parameters. After 6 months of therapy, 79.2% of patients showed improvement in anterior chamber cell numbers, and 88.2% showed improvement after 1 year. Central macular thickness measured by optical coherence tomography in patients with cystoid macular edema decreased from a mean +/- SD of 401.7 +/- 86.8 mu m to 259.1 +/- 39.5 m after 6 months of TCZ (P=0.012). The best-corrected visual acuity increased from 0.56 +/- 0.35 to 0.64 +/- 0.32 (P

Published
2017

5. FRI0430 Golimumab in Refractory Uveitis Related To Spondyloarthritis. Multicenter Study of 15 Patients

Author

Palmou-Fontana, N., primary, Calvo-Río, V., additional, Blanco, R., additional, Santos-Gomez, M., additional, Rubio-Romero, E., additional, Cordero-Coma, M., additional, Gallego-Flores, A., additional, Verόz, R., additional, Torre, I., additional, Hernández, F.F., additional, Atanes, A., additional, Loricera, J., additional, Gonzalez-Vela, M., additional, Hernandez, J.L., additional, and González-Gay, M.A., additional

Published
2016
Full Text
View/download PDF

8. Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome.

Author

Sorigue M, Nieto J, Santos-Gomez M, Sarrate E, Jiménez MJ, Morales-Indiano C, Lopez-Viaplana L, Orna E, Navarro JT, Ribera JM, and Xicoy B

Subjects
Aged, Aged, 80 and over, Anticoagulants administration & dosage, Female, Fibrinolytic Agents administration & dosage, Hemorrhage drug therapy, Humans, Incidence, Male, Middle Aged, Myelodysplastic Syndromes drug therapy, Risk Factors, Anticoagulants adverse effects, Fibrinolytic Agents adverse effects, Hemorrhage chemically induced, Hemorrhage mortality, Myelodysplastic Syndromes mortality
Abstract

Myelodysplastic syndrome (MDS) and antithrombotic medication both increase the risk of bleeding. We set out to analyze the prevalence of use, indications and bleeding risk of antithrombotic therapy in patients with MDS in a retrospective, single-center study including all patients with MDS with >20 × 10 9 /L platelets. 193 patients (59% male, median age 75 years) were included; 122 did not receive antithrombotic treatment, 51 received antiplatelet agents and 20 received anticoagulants. The cumulative incidence of major bleeding was higher in both the antiplatelet group (11.8% at 4 years, 95% confidence interval [95%CI]: 4.7-22.3%) and the anticoagulation group (21.2% at 4 years, 95%CI 6-42.5%) than in the control group (2.8% at 4 years 95%CI: 0.7-7.3%). The prevalence of use of antithrombotic medication in this cohort of patients with MDS was high and bleeding risk was increased in these patients., (Copyright © 2018 Elsevier Ltd. All rights reserved.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results